ArticleAntimicrobial agents and chemotherapy2009
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 64 citations in OpenAlex.
- A bipartite glucan synthase-remodeler module organizes branched glucan assembly in the fungal cell wall.Nature communications · 2026Article
- The Structure, Biosynthesis, and Function of β-1,6-Glucan in the Fungal Cell Wall.Biomolecules · 2026Review
- The novel antifungal agent NPD2560 perturbs the Rho1-centered signaling network to induce a cell wall integrity response.Microbiology spectrum · 2026Article
- β-1,6-Glucan plays a central role in the structure and remodeling of the bilaminate fungal cell wall.eLife · 2024Article
- BIONIC: biological network integration using convolutions.Nature methods · 2022Article
- Elicitor-Induced Metabolomics Analysis ofJournal of fungi (Basel, Switzerland) · 2022Article
- Jerveratrum-Type Steroidal Alkaloids Inhibit β-1,6-Glucan Biosynthesis in Fungal Cell Walls.Microbiology spectrum · 2022Article
- A new humanized antibody is effective against pathogenic fungi in vitro.Scientific reports · 2021Article
- Analysis and application of a suite of recombinant endo-β(1,3)-D-glucanases for studying fungal cell walls.Microbial cell factories · 2021Article
- The antifungal pipeline: a reality check.Nature reviews. Drug discovery · 2017Review
- Characterization of N-Acetylglucosamine Biosynthesis in Pneumocystis species. A New Potential Target for Therapy.American journal of respiratory cell and molecular biology · 2017Article
- Evidence for Proinflammatory β-1,6 Glucans in the Pneumocystis carinii Cell Wall.Infection and immunity · 2015Article
- Antifungal drug development: challenges, unmet clinical needs, and new approaches.Cold Spring Harbor perspectives in medicine · 2014Review
- Early state research on antifungal natural products.Molecules (Basel, Switzerland) · 2014Review
- Inhibitors of the glyoxylate cycle enzyme ICL1 in Candida albicans for potential use as antifungal agents.PloS one · 2014Article
- Review
- Antifungal drug discovery: something old and something new.PLoS pathogens · 2012Review
- KRE genes are required for beta-1,6-glucan synthesis, maintenance of capsule architecture and cell wall protein anchoring in Cryptococcus neoformans.Molecular microbiology · 2010Article
- Effect of beta-1,6-glucan inhibitors on the invasion process of Candida albicans: potential mechanism of their in vivo efficacy.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is possible that antifungal drugs with novel modes of action will provide favorable options to treat fungal infections. In the course of our screening for antifungal compounds acting on the cell wall, a pyridobenzimidazole derivative with unique activities, named D75-4590, was discovered. During treatment of Saccharomyces cerevisiae with D75-4590, (i) incorporation of [(14)C]glucose into the beta-1,6-glucan component was selectively reduced, (ii) proteins released from the cell had lost the beta-1,6-glucan moiety, and (iii) cells tended to clump, resulting in impaired cell growth. Genetic analysis of a D75-4590-resistant mutant of S. cerevisiae indicated that its primary target was Kre6p, which is considered to be one of the beta-1,6-glucan synthases. These results strongly suggest that D75-4590 is a specific inhibitor of beta-1,6-glucan synthesis. D75-4590 showed potent activities against various Candida species. It inhibited hyphal elongation of C. albicans as well. KRE6 is conserved in various fungi, but no homologue has been found in mammalian cells. These lines of evidence indicate that D75-4590 is a promising lead compound for novel antifungal drugs. To our knowledge, this is the first report of a beta-1,6-glucan inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.